Unfortunately, the medical community is resisting the use of pharmacogenomic data in clinical practice, despite regulatory authorities’ recommendations for many drugs. PBMs and consumer genomic companies can be a positive force by facilitating or advancing the use of such data.
令人遗憾的是，尽管监管部门竭力推荐多种药物，但医学界目前仍拒绝将药物基因数据应用于临床实践当中。 处方药集采企业和消费基因公司可以在推动数据的应用方面发挥积极的作用。